Warning: Missing argument 1 for get_pagelink_by_slug(), called in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/header.php on line 111 and defined in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/admin/functions-theme-basic.php on line 98

機関誌『日中医学』

特集:日中における免疫抑制薬物療法の現状と課題

巻頭言 免疫抑制薬物療法の現状と展望

愛知医科大学外科学講座(腎移植外科) 教授
小林孝彰

中国における特発性膜性腎症の免疫抑制薬適用の現状と展望

鄭州大学第一附属病院腎臓内科
劉亜飛、邢国蘭※1
※1.教授、主任医師(責任著者)

The Treatment of Idiopathic Membranous Nephropathy by Immunosuppressants in Chinese Mainland


【Abstract】
In Chinese mainland, the incidence of Idiopathic Membranous Nephropathy (IMN) is increasing. If the treatment is not efficient, IMN will gradually progress to end stage renal disease (ESRD). The specific treatment of IMN is mainly immunosuppressive therapies. The review was performed to summarize the application and progress of immunosuppressants for IMN in Chinese Mainland, so as to provide relevant evidences for clinical research and treatment.

【Key words】
Idiopathic Membranous Nephropathy, Immunosuppressants, review, Chinese Mainland

中国の血液疾患治療における免疫抑制薬物療法の現状と展望

福建医科大学附属協和病院血液科
付海英、劉彦権

中国中医科学院西苑病院血液科
劉為易、胡暁梅※1
※1.主任医師(責任著者)

Current Status and Future Insights of the Application of Immunosuppressive Drugs in Hematology in China


【Abstract】
The pathogenesis of hematological diseases is complex. Most of them are usually in critical condition with poor prognosis and difficult clinical treatment. It is a type of diseases that seriously threaten the life and health of Chinese people. In recent years, with the rapid development of basic and clinical research in immunology in the field of hematology, immunotherapy has emerged, and it is expected to improve the efficacy of the hematological diseases treated by traditional therapy. This paper will discuss the current status of the application of immunosuppressive drugs in China, with a view to the prospect of
immunosuppressive drugs in the field of hematology.

【Key words】
Hematological diseases, Blood diseases, Immunotherapy, Immunosuppressive agents

免疫抑制剤と臓器保存

旭川医科大学移植医工学治療開発講座
松野直徒※1
※1.特任教授(責任著者)

旭川医科大学病院消化管外科、肝胆膵・移植外科
松野直徒、庄中達也、高橋裕之、萩原正弘、今井浩二、横尾英樹、合地美香子、大谷将秀、古川博之

旭川医科大学病院小児外科
石井大介

首都大学東京医用工学研究室
小原弘道

Current topics of immunosuppression and preservation for organ transplantation


【Abstract】
Genetic substitution, even in the immunosuppression for organ transplantation has been promoting in national health insurance system for Japan. Intensive drug monitoring may be required in genetic substitution, especially in the case of mycofenorate mofetil. Immunosuppressive agents of which TDM monitoring is recommended to optimize the individual dose in the transplant recipients are also required to substitute from original bland to genetic, even though their pharmacokinetics are not equal. The drig monitoring may be required in even genetic MMF. There are two methods for transplant organ preservation in the world; Simple static cold preservation(CS)and machine perfusion preservation(MP). Recently, our research group reported the beneficial effects of human artificial hemoglobin vesicle, (artificial blood)as a preservation solution for MP. This study will promise ex vivo organ treatment including immunosuppression before transplantation.

【Key words】
genetic MMF, organ preservation, ex vivo immunotherapy

我が国における免疫抑制薬物療法の現状:
タクロリムスのTDM を中心に

筑波大学附属病院薬剤部
鈴木嘉治※1
※1.病院講師(責任著者)

筑波大学医学医療系臨床薬剤学 教授
筑波大学附属病院薬剤部 薬剤部長
本間真人

Current issues of immunosuppressive agents for organ transplantation in Japan.
―― TDM for tacrolimus as the typical agent


【Abstract】
Tacrolimus, a calcineurin inhibitor, is an important immunosuppressive agent in organ transplantation. Since many factors affecting tacrolimus pharmacokinetics alter the blood concentration, therapeutic drug monitoring (TDM) is required to adjust the tacrolimus dosage for individual patient. In this review, current use of tacrolimus for organ transplantation in terms of the pharmacokinetics aspects including CYP3A5 genotype, drug-food and drug-drug interaction. Switching the original formulation of tacrolimus to generic ones is also discussed in the clinical practice in Japan.

【Key words】
tacrolimus, pharmacokinetics, generic, genotype, drug-food interaction

 

架け橋 
      
      

中国との原子力災害医療交流と防護・リスクの研究の幕開け
福島県立医科大学副学長・理事長特別補佐
(長崎大学名誉教授)
山下俊一

笹川生 in China 
     
     

琉球大学の人々の温かさにふれて
中日友好病院放射線診断科 主治医師
徐 妍妍

News Letter 
~日中医学協会からのお知らせ~
      
      

日中医学協会2020年度を迎えて
日中医学協会 理事長
小川秀興

日中笹川医学奨学金制度第43期研究者募集のお知らせ

あとがき 広報委員会委員  平野俊彦
機関誌『日中医学』投稿原稿募集の
お知らせ